Deltex Medical Group PLC Share Options (6369R)

TIDMDEMG

RNS Number : 6369R

Deltex Medical Group PLC

25 September 2017

25 September 2017

Deltex Medical Group plc

("Deltex Medical" or "the Company")

Share Options

Deltex Medical Group plc (AIM: DEMG), the global leader in Oesophageal Doppler Monitoring ("ODM") announces the grant of share options to its executive directors under its Employee Share Option Scheme and the exercise by an employee of 97,560 share options under the Company's Enterprise Management Incentive scheme ('EMI').

Employee Share Option Scheme

The Board has approved the grant of 2,500,000 and 1,562,500 share options to Ewan Phillips and Jonathan Shaw respectively under the Company's 2011 Executive Share Option Scheme. The exercise price is 4 pence per share option, a premium of 23% over the closing price on 22 September 2017. These share options may ordinarily be exercised between September 2020 and September 2027 subject to relevant performance conditions which are based on achieving certain levels of compound annual sales growth.

Confirmation of Directors interest in share options

Following the grant of EMI options above, the options held by the Executive Directors are shown below:

 
 Executive        2001 Executive   2011 Executive   EMI Share 
  Director          Share Scheme     Share Scheme      Scheme       Total 
                          Number           Number      Number      Number 
---------------  ---------------  ---------------  ----------  ---------- 
 Ewan Phillips         1,000,000        5,250,000   2,995,954   9,245,954 
 Jonathan 
  Shaw                         -        1,562,500     404,762   1,967,262 
---------------  ---------------  ---------------  ----------  ---------- 
 

Additional interests

Mr Phillips and Mr Shaw have beneficial interests in 2,921,051 and 262,931 ordinary shares in the Company respectively. Following the share option exercise referred to above these holdings will represent 0.93 per cent and 0.08 per cent of the issued ordinary share capital of the Company.

Exercise of EMI share options

The Company has also issued 97,560 new Ordinary Shares of 1 pence each in the capital of the Company ("Ordinary Shares") following the exercise of options by an employee granted under the Company's EMI share option scheme. The options had an exercise price of 1 pence per share and the notice of exercise was received on 13 September 2017. Application has been made for the 97,560 new Ordinary Shares to be admitted to trading on AIM ("Admission"), and dealings are expected to commence on 29 September 2017. The new Ordinary Shares will rank pari passu with the Company's existing Ordinary Shares.

The total number of Ordinary Shares in issue following Admission will be 313,213,367. The Company does not hold any shares in treasury. Accordingly, the figure of 313,213,367 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

The following notifications are made in accordance with Article 19 of the EU Market Abuse Regulation

 
 1    Details of the person discharging managerial 
       responsibilities / person closely associated 
 a)   Name                         Ewan Phillips 
     ---------------------------  ----------------------------------- 
 2    Reason for the notification 
     ---------------------------------------------------------------- 
 a)   Position/status              Executive Director 
     ---------------------------  ----------------------------------- 
 b)   Initial notification         Initial 
       /Amendment 
     ---------------------------  ----------------------------------- 
 3    Details of the issuer, emission allowance 
       market participant, auction platform, auctioneer 
       or auction monitor 
     ---------------------------------------------------------------- 
 a)   Name                         Deltex Medical Group plc 
     ---------------------------  ----------------------------------- 
 b)   LEI                          N/A 
     ---------------------------  ----------------------------------- 
 4    Details of the transaction(s): section to 
       be repeated for (i) each type of instrument; 
       (ii) each type of transaction; (iii) each 
       date; and (iv) each place where transactions 
       have been conducted 
     ---------------------------------------------------------------- 
 a)   Description of               Conditional awards over 
       the financial instrument,    Ordinary shares of 1p each 
       type of instrument           in Deltex Medical Group 
                                    plc 
       Identification 
       code                         Identification code (ISIN) 
                                    for Deltex Medical Group 
                                    plc ordinary shares: GB0059337583 
     ---------------------------  ----------------------------------- 
 b)   Nature of the transaction     Grant of Share Options 
     ---------------------------  ----------------------------------- 
 c)   Price(s) and volume(s)       Conditional award over 
                                    2,500,000 shares under 
                                    the Deltex Medical Group 
                                    Executive Share Option 
                                    Scheme 2011 
     ---------------------------  ----------------------------------- 
 d)   Aggregated information 
       - Aggregated volume 
       - Price 
     ---------------------------  ----------------------------------- 
 e)   Date of the transaction      22 September 2017 
     ---------------------------  ----------------------------------- 
 f)   Place of the transaction     Grant of share awards occurred 
                                    outside of a trading venue. 
     ---------------------------  ----------------------------------- 
 
 
 1    Details of the person discharging managerial 
       responsibilities / person closely associated 
 a)   Name                        Jonathan Shaw 
     --------------------------  ----------------------------------- 
 2    Reason for the notification 
     --------------------------------------------------------------- 
 a)   Position/status             Executive Director 
     --------------------------  ----------------------------------- 
 b)   Initial notification        Initial 
       /Amendment 
     --------------------------  ----------------------------------- 
 3    Details of the issuer, emission allowance 
       market participant, auction platform, auctioneer 
       or auction monitor 
     --------------------------------------------------------------- 
 a)   Name                        Deltex Medical Group plc 
     --------------------------  ----------------------------------- 
 b)   LEI                         N/A 
     --------------------------  ----------------------------------- 
 4    Details of the transaction(s): section to 
       be repeated for (i) each type of instrument; 
       (ii) each type of transaction; (iii) each 
       date; and (iv) each place where transactions 
       have been conducted 
     --------------------------------------------------------------- 
 a)   Description of the          Conditional awards over Ordinary 
       financial instrument,       shares of 1p each in Deltex 
       type of instrument          Medical Group plc 
 
       Identification code         Identification code (ISIN) 
                                   for Deltex Medical Group 
                                   plc ordinary shares: GB0059337583 
     --------------------------  ----------------------------------- 
 b)   Nature of the transaction    Grant of Share Options 
     --------------------------  ----------------------------------- 
 c)   Price(s) and volume(s)      Conditional award over 1,562,500 
                                   shares under the Deltex Medical 
                                   Group Executive Share Option 
                                   Scheme 2011 
     --------------------------  ----------------------------------- 
 d)   Aggregated information 
       - Aggregated volume 
       - Price 
     --------------------------  ----------------------------------- 
 e)   Date of the transaction     22 September 2017 
     --------------------------  ----------------------------------- 
 f)   Place of the transaction    Grant of share awards occurred 
                                   outside of a trading venue. 
     --------------------------  ----------------------------------- 
 

For further information, please contact:

 
 Deltex Medical Group    01243 774 837 
  plc                     [e-mail] 
 Nigel Keen, Chairman 
 Ewan Phillips, Chief 
  Executive 
 Jonathan Shaw, Group 
  Finance Director 
 
 Nominated Adviser & 
  Broker 
 Arden Partners plc      020 7614 5900 
 Chris Hardie 
  Ciaran Walsh 
 
 
 
 Joint Broker 
 Turner Pope Investments       0203 621 4120 
  (TPI) Ltd                     [e-mail] 
 Ben Turner 
  James Pope 
 
 Financial Public Relations 
 IFC Advisory Ltd              0203 053 8671 
 Tim Metcalfe 
  Graham Herring 
  Heather Armstrong 
 

Notes for Editors

Deltex Medical manufactures and markets haemodynamic monitoring technologies. Deltex Medical's ODM is the only technology to measure continuously blood flow in the central circulation in real time. Minimally invasive, easy to set up and quick to focus, the technology generates a low-frequency ultrasound signal, which is highly sensitive to changes in flow and measures them immediately. Deltex has been the only company in the enhanced haemodynamic space to build a robust and credible evidence base proving the clinical and economic benefits of its core technology, ODM. Randomised, controlled trials using Doppler have demonstrated that early fluid management intervention will reduce post-operative complications, reduce intensive care admissions, and reduce the length of hospital stay.

Company goal

ODM is increasingly recognised as a standard of care for patients undergoing major surgery and in critical care. The broader clinical area of haemodynamic management of which ODM is a core constituent is also now becoming widely accepted as an important major new medical modality. Consequently, the Company's focus is on maximising value from the opportunities presented as enhanced haemodynamic management is adopted into routine clinical practice around the world.

The Company is currently in the implementation phase of achieving this goal in a number of territories worldwide, operating directly in the UK, USA, Spain and Canada and through distribution arrangements in a further 30 countries.

There are over 3,400 monitors installed in hospitals around the world and around 700,000 patients have been treated to date using Deltex Medical's single patient disposable probes.

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHUSUNRBUAKUAR

(END) Dow Jones Newswires

September 25, 2017 02:01 ET (06:01 GMT)